Publicar

EFEITOS CARDIOPROTETORES DA SEMAGLUTIDA EM PACIENTES OBESOS: UMA REVISÃO INTEGRATIVA

Doi: 10.47094/978-65-284-0234-2/7

PALAVRAS CHAVE: Semaglutida. Obesidade. Mortalidade cardiovascular.

KEYWORDS: Semaglutide. Obesity. Cardiovascular mortality.

ABSTRACT:
INTRODUCTION: Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been studied for its beneficial effects on metabolic control and weight loss. Evidence indicates that it may also significantly reduce fatal cardiovascular events in obese individuals, regardless of the presence of type 2 diabetes. OBJECTIVE: To evaluate, through an integrative review, the effects of semaglutide on reducing cardiovascular mortality in obese patients.

Autores

  • Ana Luísa Carvalho Gonçalves

  • Elias Emanuel Silva Mota

  • Gabriel Virgílio Ferreira Aleixo

  • Marco Túlio Kaji Ferreira dos Santos

Download